Mesothelioma Symptoms, Mesothelioma Types and Mesothelioma Lawsuits
WHAT IS MALIGNANT PLEURA MESOTHELIOMA?
The pleura is a thin, cushioning membrane that protects the lungs in which fluid within the pleura membrane separates two layers of tissue in the chest cavity. Pleural mesothelioma, also known as malignant pleural mesothelioma, is the most common form of mesothelioma. There are 1500 to
2250 new cases of malignant pleural mesothelioma each year and unfortunately the survival rate of malignant pleural
mesothelioma is low but the earlier it is detected the higher the survival rate. In most cases those diagnosed with malignant pleural mesothelioma have up to 1.5 years to live and in extreme cases the survival time could be as high as five years. Most cases of malignant pleural mesothelioma are diagnosed during the latent stages of this type of cancer thus making it difficult to prolong the lives of those infected. The majority of malignant pleura mesothelioma cases are caused from exposure to asbestos.
WHO IS AT RISK FOR MALIGNANT PLEURA MESOTHELIOMA? MALIGNANT PLEURAL MESOTHELIOMA TREATMENT The treatments for malignant pleural mesothelioma mainly consist of chemotherapy, surgery, radiation therapy, and immunotherapy. Usually malignant pleural mesothelioma requires a combination of these treatments and some are used more than others depending on the individual. There are also clinical trials that may also provide another alternative to the pleural mesothelioma patient. These clinical trials may provide new and promising treatments malignant pleural mesothelioma. A list of links are provided here with the most up to date information on clinical trials for pleural mesothelioma sufferers Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
The highest risk occupations for malignant pleura mesothelioma include: home re modelers, construction workers,insulation manufacturers and insulation installers, automotive and railroad workers, gas mask manufacturers, some factory workers where asbestos is used and some miners. Just because you do not work in these industries does not mean you are not at risk for malignant pleural mesothelioma; asbestos fibers may be attached to the clothes of these workers and carried into the household. Malignant pleura mesothelioma may take 20 to 50 years to develop; much depends on how much asbestos you were exposed to. Since the latency in diagnosing malignant pleura mesothelioma most cases appear in people between the ages of 50 to 70 years old.
MALIGNANT PLEURA MESOTHELIOMA SYMPTOMS
Malignant pleura mesothelioma symptoms may be confused with many other ailments at first due to its latent nature in developing. Usually several weeks or month can pass before a correct diagnosis can be made. Malignant pleura mesothelioma symptoms initially appear no different than other symptoms from a flu or a cold. You may have a persistent cough and hoarse voice or trouble swallowing and breathing. A fever may be present along with sweating,fatigue and muscle weakness. There also could be swelling in the face and arms along with lower back pain or pain on the side of the chest. All of these may point to malignant pleura mesothelioma and it is recommended that you see a doctor and tell him your work history or possible exposure to asbestos.
In a study conducted by Dr. Philipe Chahinian, a leading oncologist, conducted five studies in malignant pleura mesothelioma patients who encountered the symptoms listed below in varying degrees;
Shortness of Breath 6% to 60% of cases
Chest Pain 33% to 71% of cases
Both of the Above 19% to 28% of cases
Cough 3% to 28% of cases
Spitting of blood 1% to 6% of cases
Hoarseness 1% to 3% of cases
Difficulty Swallowing 0% to 1% of cases
Weight Loss 14% to 29% of cases
Fever 3% to 33% of cases
Asymptomatic 3% to 4% of cases
Pleural effusion 74% to 84% of cases
MALIGNANT PLEURA MESOTHELIOMA STAGES
Staging is defined as what level malignant pleura mesothelioma has spread within the body. It assists the doctor in determining what the outlook is and treatment to administer to the patient. Since malignant pleural mesothelioma is the most common type of mesothelioma it is the only one to have a staging system issued to it. The American Joint Committee on Cancer has developed the most common system used to determine the stage of malignant pleura mesothelioma. The systems name, TNM, is an acronym for Tumor Node Metastasized.
The T tells the doctor how far the main tumor has spread
The N tells the doctor how far the cancer has traveled to regional lymph nodes.
The M tells the doctor whether the cancer has spread to other regions of the body
There is a number system associated with each letter in the TNM system,1-4, which tells the doctor to which degree the malignant pleural mesothelioma has spread throughout the body. i.e. T2N1MO
March 2009 Eli Lily Clinical Trials for malignant pleural mesothelioma
June 2009 Clinical Trial Database for malignant pleural mesothelioma
June 2009 updated information on Clinical Trials
2009 Molmed FDA approval information for malignant pleural mesothelioma
ARTICLES AND SOURCES FOR MALIGNANT PLEURAL MESOTHELIOMA
List updated July 2009
Future Oncology - Pleural Mesothelioma
Contemporary Management of Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma : a phase II trial with docetaxel
Laparoscopy: an important tool in the staging of malignant pleural mesothelioma
Screening for Malignant Pleural Mesothelioma in Individuals
Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study
Early Response Evaluation in Malignant Pleural Mesothelioma
The use of Pemetrexed for the treatment of malignant pleural mesothelioma
Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma
First-Line Chemotherapy for Malignant Pleural Mesothelioma
Current chemotherapeutic treatment of malignant pleural mesothelioma
To Contact Us Click Here